Pfizer's Bulging Drug Pipeline

摘要

In this dismal economy, it would surprise fewrnpeople if Pfizer (PFE) were to announce job cuts or scale back its sales forecasts. Even so, some pros believe it's a timely buy because of its long-depressed stock price and rich pipeline of new drugs-plus an attractive dividend yield of 7.7%. Pfizer is banking on 25 new products in Phase 3 late-stage trials, notes Wendell Perkins, chief investment officer at Optique Capital Management,rnwhich owns shares. Meanwhile, Pfizer's Lyrica, a pain remedy already on the market, is being tested for conditions such as epilepsy and anxiety disorder.